Floatz logo

TEGAFUR

Stage II/III

Institut Cancerologie de l'OuestSmall moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Stage II/III cohort.

Asset / SponsorPhaseRating
Datopotamab Deruxtecan
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Artesunate
UNC Lineberger Comprehensive Cancer Center
Phase 1CC

Same molecule, other indications

TEGAFUR is also rated in:

Adjuvant ChemotherapyDormant
B
Indicative ·
59 / 100
View asset →
rectal cancerDormant
B
Indicative ·
59 / 100
View asset →
breast cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →